Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 3, 2005, Pages 1263-1271

  Heise, Christopher E ^a   Pahuja, Anil ^a   Hudson, Sarah C ^a   Mistry, Monica S ^a   Putnam, Amy L ^b   Gross, Molly M ^a   Gottlieb, Peter A ^b   Wade, Warren S ^a   Kiankarimi, Mehrak ^a   Schwarz, David ^a   Crowe, Paul ^a   Zlotnik, Albert ^a   Alleva, David G ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); LIGAND; N [3 (4 ETHOXYPHENYL) 4 OXO 3,4 DIHYDROPYRIDO[2,3 D]PYRIMIDIN 2 YL]ETHYL N PYRIDIN 3 YLMETHYL 2 (4 FLUORO 3 TRIFLUOROMETHYLPHENYL)ACETAMIDE; NBI 74330; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CALCIUM MOBILIZATION; CHEMOTAXIS; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ACETAMIDES; CELL LINE, TUMOR; CHEMOKINES, CXC; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; PYRIMIDINES; RECEPTORS, CHEMOKINE;

EID: 21144439416     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.083683     Document Type: Article

References (36)

1. Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, Loy M, Binotto G, Valente M, Trentin L, and Semenzato G (2001) Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 158:1703-1711.
2. Baggiolini M, Dewald B, and Moser B (1997) Human chemokines: an update. Annu Rev Immunol 15:675-705.
3. Balashov KE, Rottman JB, Weiner HL, and Hancock WW (1999) CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 96:6873-6878.
4. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
5. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, et al. (1998) Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187: 2009-2021.
6. Cox MA, Jenh CH, Gonsiorek W, Fine J, Narula SK, Zavodny PJ, and Hipkin RW (2001) Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 59:707-715.
7. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, and Luster AD (2002) IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168:3195-3204.
8. Farber JM (1997) Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 61:246-257.
9. Frigerio S, Junt T, Lu B, Gerard C, Zumsteg U, Hollander GA, and Piali L (2002) Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med 8:1414-1420.
10. Gao P, Zhou XY, Yashiro-Ohtani Y, Yang YF, Sugimoto N, Ono S, Nakanishi T, Obika S, Imanishi T, Egawa T, et al. (2003) The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol 73:273-280.
11. Gasperini S, Marchi M, Calzetti F, Laudanna C, Vicentini L, Olsen H, Murphy M, Liao F, Farber J, and Cassatella MA (1999) Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC) and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol 162:4928-4937.
12. Gattass CR, King LB, Luster AD, and Ashwell JD (1994) Constitutive expression of interferon gamma-inducible protein 10 in lymphoid organs and inducible expression in T cells and thymocytes. J Exp Med 179:1373-1378.
13. Gautam S, Battisto J, Major JA, Armstrong D, Stoler M, and Hamilton TA (1994) Chemokine expression in trinitrochlorobenzene-mediated contact hypersensitivity. J Leukoc Biol 55:452-460.
14. Gu JL, Lu W, Xia C, Wu X, and Liu M (2003) Regulation of hematopoietic-specific G-protein Galpha15 and Galpha16 by protein kinase C. J Cell Biochem 88:1101-1111.
15. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, and Luster AD (2001) Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 193:975-980.
16. Hancock WW, Wang L, Ye Q, Han R, and Lee I (2003) Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 15:479-486.
17. Hoare SR, Sullivan SK, Ling N, Crowe PD, and Grigoriadis DE (2003) Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol Pharmacol 63:751-765.
18. Kozak M (1981) Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosomes. Nucleic Acids Res 9:5233-5262.
19. Loetscher M, Loetscher P, Brass N, Meese E, and Moser B (1998) Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 28:3696-3705.
20. Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, Libby P, and Luster AD (1999) Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Investig 104:1041-1050.
21. Medina J, Collins T, Johnson M, Li A-R, Fu Z, Liu J, Marcus A, Tonn G, Schall T, and Ye Q (2004) Discovery and development of a CXCR3 antagonist T487 as therapy for Th1-mediated immune disorders, in 29th National Medicinal Chemistry Symposium; 2004 June 27-July 1, University of Wisconsin-Madison, WI.
22. Medina JC and Johnson MG (2002) inventors, Tularik Inc., assignee. CXCR3 antagonists. WO02083143. 2002 Oct 24.
23. Melter M, Exeni A, Reinders ME, Fang JC, McMahon G, Ganz P, Hancock WW, and Briscoe DM (2001) Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 104:2558-2564.
24. Mohan K, Ding Z, Hanly J, and Issekutz TB (2002) IFN-gamma-inducible T cell alpha chemoattractant is a potent stimulator of normal human blood T lymphocyte transendothelial migration: differential regulation by IFN-gamma and TNF-alpha. J Immunol 168:6420-6428.
25. Ott TR, Pahuja A, Lio FM, Mistry MS, Gross M, Hudson SC, Wade WS, Simpson PB, Struthers RS, and Alleva DG (2004) A high throughput chemotaxis assay for pharmacological characterization of chemokine receptors: utilization of U937 monocytic cells. J Pharmacol Toxicol Methods, in press.
26. Patel DD, Zachariah JP, and Whichard LP (2001) CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 98:39-45.
27. Ruth JH, Rottman JB, Katschke KJ Jr, Qin S, Wu L, LaRosa G, Ponath P, Pope RM, and Koch AE (2001) Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 44:2750-2760.
28. Salmaggi A, Gelati M, Dufour A, Corsini E, Pagano S, Baccalini R, Ferrero E, Scabini S, Silei V, Ciusani E, and De Rossi M (2002) Expression and modulation of IFN-gamma-inducible chemokines (IP-10, Mig and I-TAC) in human brain endothelium and astrocytes: possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis. J Interferon Cytokine Res 22:631-640.
29. Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, and Karin N (2002) Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol 169:2685-2693.
30. Swinney DC (2004) Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 3:801-808.
31. Wang X, Li X, Schmidt DB, Foley JJ, Barone FC, Ames RS, and Sarau HM (2000) Identification and molecular characterization of rat CXCR3: receptor expression and interferon-inducible protein-10 binding are increased in focal stroke. Mol Pharmacol 57:1190-1198.
32. Wedderburn LR, Robinson N, Patel A, Varsani H, and Woo P (2000) Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum 43:765-774.
33. Xanthou G, Williams TJ, and Pease JE (2003) Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Eur J Immunol 33:2927-2936.
34. Xie JH, Nomura N, Lu M, Chen SL, Koch GE, Weng Y, Rosa R, Di Salvo J, Mudgett J, Peterson LB, et al. (2003) Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. J Leukoc Biol 73:771-780.
35. Yang YF, Mukai T, Gao P, Yamaguchi N, Ono S, Iwaki H, Obika S, Imanishi T, Tsujimura T, Hamaoka T, and Fujiwara H (2002) A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur J Immunol 32:2124-2132.
36. Zlotnik A and Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121-127.